Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 12:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 411 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 150 Min/Week Clear all
Completed Phase 2 Interventional

Reduction of Triglycerides in Women on Hormone Replacement Therapy

NCT00023543
View directory record Official record
Conditions
Cardiovascular Diseases, Atherosclerosis, Postmenopause, Heart Diseases
Interventions
Diet, fat-restricted, Exercise
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
52 Years to 60 Years · Female only
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 11, 2026, 12:16 PM EDT
Withdrawn Not applicable Interventional

Prenatal Breastfeeding Education

NCT04549129
View directory record Official record
Conditions
Breast Feeding
Interventions
Breastfeeding education video, Breastfeeding website, Usual breastfeed education
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Quincy, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Sep 11, 2026, 12:16 PM EDT
Active, not recruiting Not applicable Interventional

Expanding Delivery of an Evidence-based Weight-loss Intervention to Enhance Access and Reach Underserved Groups After TBI

NCT05699772
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Telehealth-delivered Group Lifestyle Balance for people with TBI (tGLB-TBI), Brain Health Group (BHG)
Behavioral
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 11, 2026, 12:16 PM EDT
Not yet recruiting Not applicable Interventional

A Physical Activity Program Compared to Health Education for Improving Memory and Attention in Hispanic Women With Newly-Diagnosed Stage I-IIIa Breast Cancer, MAMA Trial

NCT07331077
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Cancer-related Cognitive Dysfunction
Interventions
Accelerometry, Aerobic Exercise, Electronic Health Record Review, Functional Magnetic Resonance Imaging, Gait Assessment Test, Health Education, Interview, Neurocognitive Assessment, Physical Performance Testing, Questionnaire Administration
Procedure · Other · Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 11, 2026, 12:16 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lifestyle Intervention and Metformin for Women With Polycystic Ovary Syndrome (PCOS)

NCT00151411
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin, Placebo, Lifestyle Intervention
Drug · Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
12 Years to 39 Years · Female only
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Sep 11, 2026, 12:16 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Comparing Self-paced Versus Moderate Intensity Physical Activity Recommendation for Midlife Adults

NCT05285748
View directory record Official record
Conditions
Physical Inactivity
Interventions
Self-Paced Intensity Physical Activity, Prescribed Moderate Intensity Physical Activity
Behavioral
Lead sponsor
Brown University
Other
Eligibility
50 Years to 64 Years
Enrollment
258 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 11, 2026, 12:16 PM EDT
Completed Phase 2 Interventional Results available

Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

NCT01784068
View directory record Official record
Conditions
Chronic Myelogenous Leukemia
Interventions
Nilotinib followed by treatment-free
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
10
States / cities
Fort Myers, Florida • Miami Lakes, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 11, 2026, 12:16 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

NCT03447249
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-659/TEZ/IVA, IVA, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
48
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Sep 11, 2026, 12:16 PM EDT
Recruiting Not applicable Interventional

Muscle and Movement With Anti-Obesity Medications

NCT06645470
View directory record Official record
Conditions
Obesity and Overweight
Interventions
Standard Medical Care (SMC), Monitoring Contacts, Aerobic Training, Resistance Training, Nutrition Education
Other · Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 11, 2026, 12:16 PM EDT
Recruiting Not applicable Interventional

Does Blood Flow Restriction Training Improve Quadriceps Function After Arthroscopic Knee Surgery?

NCT03096366
View directory record Official record
Conditions
Quadriceps Atrophy, ACL Reconstruction
Interventions
Blood flow restriction, Physical therapy
Device · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
14 Years to 55 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Sep 11, 2026, 12:16 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma

NCT05188729
View directory record Official record
Conditions
Basal Cell Carcinoma, Skin Cancer, Cancer of the Skin, Basal Cell, Cancer of the Skin, Carcinoma
Interventions
Part 1: VP-315 3 Day Dosing/Week, Part 2: VP-315 3 Day Dosing/Week - Loading Dose, Part 2: VP-315 3 Day Dosing/Week - No Loading Dose, Part 2: VP-315 2 Day Dosing/Week - Split Dose, Part 2: VP-315 3 Day Dosing/Week - Split Dose
Drug
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
San Diego, California • Boca Raton, Florida • Coral Springs, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Sep 11, 2026, 12:16 PM EDT
Recruiting Not applicable Interventional

Proof-of-concept of a Behavioral Intervention to Improve the Cardiovascular Health of People Living With HIV

NCT07105007
View directory record Official record
Conditions
HIV, Heart Failure
Interventions
Exercise Intervention, Tailored Education sessions, Behavioral coaching, Mobile health support, General education
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 11, 2026, 12:16 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

NCT02422186
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (New Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
65 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
San Diego, California • New Haven, Connecticut • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 11, 2026, 12:16 PM EDT
Completed Not applicable Interventional

Exercise in Improving Health and Quality of Life in Breast Cancer Survivors

NCT03679559
View directory record Official record
Conditions
Invasive Breast Carcinoma
Interventions
Best Practice, Exercise Intervention (home walking program and resistance training), Exercise Intervention (home-based Zumba program and resistance training), Exercise Intervention (HIIT program and resistance training), Informational Intervention, Laboratory Biomarker Analysis, Monitoring Device, Quality-of-Life Assessment, Questionnaire Administration
Other · Behavioral · Device
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Not listed
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Sep 11, 2026, 12:16 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Blossom Project: "BlossomUP" Methods to Decrease Sedentary Time in Pregnancy

NCT02909725
View directory record Official record
Conditions
Sedentary Lifestyle, Diabetes Mellitus, Gestational
Interventions
Limit accumulation of sedentary time, Walk, Normal daily routine; Usual Care
Other
Lead sponsor
Iowa State University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Sep 11, 2026, 12:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Quit and Fit: A Tobacco Cessation and Energy Balance Pilot for African Americans

NCT02103582
View directory record Official record
Conditions
Smoking Cessation
Interventions
Intervention
Other
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 69 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Sep 11, 2026, 12:16 PM EDT
Completed Phase 3 Interventional

SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma

NCT00002548
View directory record Official record
Conditions
Multiple Myeloma
Interventions
recombinant interferon alfa, carmustine, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, melphalan, prednisone, vincristine sulfate, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 70 Years
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
34
States / cities
Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 11, 2026, 12:16 PM EDT
Completed Not applicable Interventional

A Home-Based Walking Program and rTMS in Helping Breast Cancer Survivors Get More Physical Activity

NCT03789877
View directory record Official record
Conditions
Cancer Survivor, Invasive Breast Carcinoma
Interventions
Physical Activity, Questionnaire Administration, Repetitive Transcranial Magnetic Stimulation, Sham Intervention
Other · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Sep 11, 2026, 12:16 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder

NCT01080807
View directory record Official record
Conditions
Excessive Sleepiness
Interventions
Armodafinil, Matching Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
63
States / cities
Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2012 · Synced Sep 11, 2026, 12:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility of Therapy Integrating Peer-sharing, Technology, Aerobic and Resistance Training (TIPSTART)

NCT04813198
View directory record Official record
Conditions
Group Meetings
Interventions
TIPSTART
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years to 34 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Sep 11, 2026, 12:16 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Graded Exercise Hypoxia Testing

NCT06901284
View directory record Official record
Conditions
Hypoxia
Interventions
Graded Exercise Test, Graded Hypoxia Exercise Test
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 11, 2026, 12:16 PM EDT
Terminated Phase 2 Interventional Results available

Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC

NCT04524689
View directory record Official record
Conditions
Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
Interventions
SAR408701 (Tusamitamab ravtansine), Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 11, 2026, 12:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.

NCT03767582
View directory record Official record
Conditions
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Interventions
Stereotactic Body Radiation (SBRT), Nivolumab, CCR2/CCR5 dual antagonist, GVAX
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 11, 2026, 12:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CrossFit Exercise to Improve Glucose Control for Overweight and Obese Adults

NCT02185872
View directory record Official record
Conditions
Hyperglycemia
Interventions
High-Intensity Functional Training, Aerobic and Resistance Training
Other
Lead sponsor
Kansas State University
Other
Eligibility
18 Years to 40 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Manhattan, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Sep 11, 2026, 12:16 PM EDT